Hepatitis-associated antigen in patients with cancer. by Viola, M. V. et al.
YALE JOURNAL OF BIOLOGY AND MEDICINE 45, 64-69 (1972)
Hepatitis-Associated Antigen in Patients with Cancer
MICHAEL V. VIOLA
Medical Onicology Section, Departmtlenzt of Medicine, Howard University College
of MIedicinie, Washitngton, D.C.
ALFRED M. PRINCE
Virology Laboraato-y, New York Blood Cenzter, and Depar-tu7lenit of Pathology,
ANew York Hospital-Cortnell Mledical Cenlter, New York, New York
ELLIOT ALPERT
Departmenet of Mlledicitne, Hairvard Aledical School, Departmient of Medicinie (G.I. Unit)
MIassachl setts Genieral Hospital anid the Depar-tment of Mledicine (1111 innnology Unit)
Robert B. Brighain Hospital, Boston, Mlassachutsetts
Received for puiblication 15 June 1971
The hepatitis-associated antigen (HAA) (Australian antigen) is either the in-
fective agent of viral hepatitis or a virus-related protein(l). It is present in the
blood during the incubation period and early clinical course of acute viral hepa-
titis in adults(l,2). The presence of the HAA in Krugman's long incubation
hepatitis (MS-2) and its absence in childhood hepatitis, epidemic hepatitis, and
in short incubation hepatitis (MS-1) indicates it is associated with the serum
hepatitis virus (s)(2,3). The antigen persists for longer periods in the blood of
some patients with chronic active hepatitis(4,5) and dialysis-associated hepa-
titis(6). It is frequently present in the serum of patients with Down's syndrome(7),
lepromatous leprosy(8) and certain types of leukemia(7,9-11).
We have investigated the frequency of HAA in the sera of patients with a
wide spectrum of neoplastic diseases, including primary and metastatic liver
neoplasms. Many of the patients studied had received multiple transfusions and
were being treated with immunosuppressant drugs.
METHO;DS
Sera Samples. Sera were obtained from 789 patients with biopsy proven neo-
plastic diseases in a number of institutions including Memorial Hospital for
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Canicer and( Allied Diseases, M. D. Anderson Hospital and from patients with
lhepatoma in Uoganda. Sera were stored at -20. The African patients with hlepa-
toma liave beein dlescr-ibe(d in detail elsewlhere(12). Age, sex, meclical, and trans-
fusion hiistory wvere noted on all patients. Data was statistically analyzed using the
clhi-square test witlh Yates correctioni.
Imnilin,odiffiisioni Techlntique. All sera were testedI for the presence of HAA
by the micro-Otuclhterlony immuinodiffusion teclhnique describe(d previously(l).
Tlhe antisera employed (seru-m S) were 4-fold concentrated serum from a multi-
ply transftused patient witlh lhemophilia(l).
RESULTS
Positive Sem. Twelve of 789 sera samples were positive for HAA (Table 1).
The highlest incidlence of positive sera occurred in patients with liver cancer
(4.3%-), 1breast cancer (2.8%), aanl( in patients witlh multiple myeloma (2.4%).
Two patients witli HAA (breast, Hodgkin's Disease) hadl clinically stuspected,
bIut inot biopsy proveii, posttransfusion lhepatitis. Fotur adclitional patients (breast
cervix, hepatoma, an(d myeloma) lhad a hiistor-y of multiple transfusions. The re-
maining lpatients witlh letectable antigen lhad no history of previonis transfusions
of bloocl products, slhared needlIes, shellfislh ingestion or close exposure to pa-
TABLE 1
1)ISTRIBIUTION OF HAA IN PATIENTS WtITH CANCER
Neoplassm No. positivc/nio. tested % Positive
Br-east 2/71 2.8
Choriocarcinoma. 0/5 0
Gastroinitestinal 0/49 0
Geniitouiriniary 0/17 0
Gynecological 1/116 0.8
Leutkemia 1/119 0.8
Liver, hepatocarcinoma 4/89 4.4
U.S., France 1/55 1.9
Ugand(la 3/34 8.8
Liver, cholangeocarcinioma 0/5 0
Lung 0/31 0
Lymphoma 1/117 0.8
Melanioma 0/9 0
Mtiltiple myeloma 3/124 2.4
Oro-naso-pharynx 0/11 0
Polycythemia 0/3 0
Sarcomas 0/10 0
Skin 0/7 0
Thyroid 0/4 0
Miscellaneous 0/2 0
Total 12/789 1.5
Normal Controls, USAa 292/27,387 0.08
Normal Controls, Ugandaa 6/311 1.9
a Randomly selected, healthy individuals.
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tients with hepatitis. They had all received parenteral injections of medication.
One of 24 patients with chronic lymphocytic leukemia had detectable serum
antigen. He had not received transfusions and had normal liver function tests.
No other patients with leukemia had detectable antigen. Ten of the 12 patients
with detectable antigen had normal liver function tests. There appeared to be
no relationship between age of the patient and occurrence of antigen.
Primary and metastatic liver neoplasms. Four of 94 patients with primary liver
cancer had detectable HAA. The incidence of antigen in patients with hepatocar-
cinloma in Ugan(la (3/34, 8.8%) was considerable higlher than that detected in
well individuals in that country (6/311, 1.9%2Q), however not significant at the
5% level (.1 > p > .05). None of the African patients with detectable antigen
hacl received blood transfusions. The one positive American patient with hepa-
tocarcinoma had received 4 units of blood, fourteen days before detection of the
antigen- in his blood. It should be noted that the incidence of HAA in well in-
dividluals in Uganda (1.9%,7o) is significantly higher than for similar individuals
in the United States (22/27, 387; 0.08%)(2).
Eighty-seven patients had abnormal liver function tests associated with biopsy
or liver scan documented liver metastases. None of these patients witlh liver
metastases had detectable HAA.
Additional clinical data. One hundred thirty patients received b)lood trans-
fusions (average: 6 units/patient) witlhin 6 months of having their blood tested
for HAA. Thirty-two of these patients received transfusions (average: 4.1 units/
patient) in the week before lhaving the serum sample drawn. Four of the 130
transfused patients were positive for HAA.
The HAA was not found in 174 patients who were receiving cytotoxic drug
or prednisone tlherapy for at least two weeks. 78 of the patients receiving drug
tlherapy had total white counts below 5000/mm3 and 28 patients had wlhite
counts below 2500/mm3 as a result of therapy.
DISCUSSION
With the exception of African patients with hepatocarcinoma, there was no
suggestion of a correlation between cancer type and presence of HAA. Previous
studies have shown an increased incidence of Australian antigen in patients with
leukemia, especially of the acute granulocytic, acute lymphocytic, and chronic
lymphocytic types(9-1 1). Our findings do not confirm this association. Only one
of 119 leukemic patients had detectable antigen. This group included 26 patients
with acute granulocytic and 34 patients with acute lymphocytic types, most of
whom had received multiple transfusions and were receiving aggressive cytotoxic
drug therapy. One of 24 patients with chronic lymplhocytic leukemia had de-
tectable antigen. It slhould be noted that our series of leukemic patients is smaller
than those previously reported demonstrating a higher incidence of HAA.
As stated in the introduction, HAA is found only transiently in the blood of
patients with acute viral hepatitis, but it persists in some patients with chronic
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active lhepatitis(4,13,15) and chronic anicteric viral hepatitis. A number of clinico-
patlhological studies lhave demonstrated that chronic anicteric hepatitis can be a
precursor of cirrhosis(l6,17). Because approximately two-thirds of patients with
lhepatoma also have cirrhosis, usually of the "postnecrotic" type, it is of im-
portance to (letermine the role of the hlepatitis virus in the pathogenesis of pri-
mary liver cancer(12,18). It has been postulated that the high incidence of hepa-
titis ancd otlher causes of liver impairment in Africa, predispose affected individ-
uials to the effects of clhemical hepatocarcinogens (e.g., mycotoxins)(19). Smitli
and Blumberg(20) stu(lied 65 patients with lhepatoma from Asia, Africa, and the
Unitedl States and( fouLnd the inci(lence of antigen in the hepatoma patients no
greater than in the controls. However, tlhree studies have shown a relationship
between hepatocellular carcinoma and the HAA in three different areas of the
world(21-23). Vogel's series from Uganda demonstrated the antigen in 18 of 45
patients writlh hepatocellular carcinoma. The antigen tended to occur in younger
patients in that series. In our stu(ly only one of 55 non-African patients with
hepatoma lhad detectable antigen and he had received bloodl transfusions. How-
ever, the inicidence of HAA in the Ugandan hlepatoma patients (8.8%) was con-
si(lerably hiiglher thain in the control population, (1.9%"), altlhouglh not significant
at the 5%7O level. The number of patients studied was small andl the controls were
nonhospitalized well inc(ivicluals and, tlherefore, not strictly comparable. How-
ever, these results wouild in(licate fturtlher studies are necessary, specifically
examination of hepatomia tisstue for the pr-esence of intracellular antigen and
the stuLdy of larger numnl)ers of patients witlh lhepatoma and well chosen control
ser(a.
It lhas been postuLlated that the frequency of the antigen carrier state in pa-
tieints witlh 1)owns sy,ndlrome, lepromatous leprosy, and leukemia is cause(d by
the altere(d lhost (lefenise meclhaniisms founcd in these patients(7,10,24). M\Iost cer-
tainlly at imnuml)er of ouir patients lhad alteredl immune status both as a result of
immunostuppressant dri-ug tlherapy an(l because of primary hematopoietic malig-
nancy. Examiinling single serum specimens with a relatively insensitive technique,
it appears that this type of immuntle suppression does not predlispose to tlle HAA
carrier state even thotugh this group of patients receives freqLent transftusions.
Altlhotuglh a(lditional positive sera may be obtaine(d by serial sample collections,
it is unlikely that a more sensitive test system (e.g., complement fixation) woulcd
cletect more HAA carriers(25).
SUMMARY
The sera of 789 patients with neoplastic diseases were studied for the presence
of lhepatitis-associated antigen (HAA) using an immunodiffusion teclhnique.
Twelve patients had detectable serum antigen. Six of the twelve had acute viral
lhepatitis or had received transfusions. There was no strong correlation between
cancer type and detectable antigen. The frequency of HAA in African patients
witlh hepatoma was hiiglher than in controls, but was not significant at the 5%
6768 VIOLA, PRINCE, and ALPERT
level. One of 119 patients with leukemia lhad detectable antigen. In examining
single seruim specimens using a relatively insensitive teclhnique, we could not
detect an antigen carrier state in patients witlh lhematopoietic malignancies even
tlhoutglh they were subjected to immunosuppressive (Irug therapy and frequent
bloodl transfusions.
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